Open AccessComparison of HER 2 expression between primary colorectal cancer and their corresponding metastases
Author(s) -
Lee WonSuk,
Park Yeon Ho,
Lee Jung Nam,
Baek JeongHeum,
Lee TaeHoon,
Ha Seung Yeon
Publication year - 2014
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.228
Subject(s) - colorectal cancer , kras , medicine , metastasis , immunohistochemistry , primary tumor , gene duplication , fluorescence in situ hybridization , oncology , cancer , metastatic breast cancer , lung , lung cancer , breast cancer , pathology , biology , gene , biochemistry , chromosome
The aim of this study was to compare human epidermal growth factor 2 ( HER 2) status in primary colorectal cancer and paired liver or lung metastasis. Gene amplification of HER 2 has been intensively evaluated in contemporary oncology, especially in breast and stomach cancer. The knowledge of HER 2 status in primary and metastatic sites may be of potential value for therapeutic decision making in metastatic colon cancer. The HER 2 status was assessed by fluorescence in situ hybridization ( FISH ) and immunohistochemistry ( IHC ) in 94 colorectal cancer with corresponding liver or lung metastases. HER 2 amplification was present in 19 of the 188 (10.1%) of both primary and metastases combined. Four (4.6%) patients showed HER 2 amplification in the metastasis and 10 (10.6%) patients showed HER 2 amplification in the primary tumor. In 14 cases (14.8%), the HER 2 status of the primary lesions was different from that of the associated metastases. The presence of HER 2 overexpression in KRAS mutant colon cancer was found in 5.3%. No relationship was found between HER 2 expression and KRAS status ( P = 0.486). The evidence of HER 2 positive metastatic lesion and primary colorectal cancer suggest that HER 2 assessment might be considered in selected cases when this may help change the therapeutic decision.